Arsenite induced poly(ADP-ribosyl)ation of tumor suppressor P53 in human skin keratinocytes as a possible mechanism for carcinogenesis associated with arsenic exposure

Toxicology and Applied Pharmacology

Volumn 243, Issue 3, 2010, Pages 399-404

  Komissarova, Elena V ^a   Rossman, Toby G ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arsenite; Carcinogenesis; Keratinocytes; p21; p53; PARP

Indexed keywords

ARSENIC TRIOXIDE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; GENE EXPRESSION; HUMAN; HUMAN CELL; KERATINOCYTE; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ARSENITES; BLOTTING, WESTERN; CARCINOGENS; CELL LINE; CELL SURVIVAL; HUMANS; IMMUNOPRECIPITATION; KERATINOCYTES; P21-ACTIVATED KINASES; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 77049125910     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.12.014     Document Type: Article

References (53)

1. Abbas T., and Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9 (2009) 400-414
2. Boswell S.A., Ongusaha P.P., Nighiem P., and Lee S.W. The protective role of a small GTPases RhoE against UVB-induced DNA damage in keratinocytes. J. Biol. Chem. 282 (2007) 4850-4855
3. Boukamp P., Petrussevska R.T., Breitkreutz D., Hornung J., Markham A., and Fusenig N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106 (1988) 761-771
4. Braithwaite A.W., Royds J.A., and Jackson P. The p53 story: layers of complexity. Carcinogenesis 26 (2005) 1161-1169
5. Burns F.J., Uddin A.N., Wu F., Nadas A., and Rossman T.G. Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: a dose-response study. Environ. Health Perspect. 112 (2004) 599-603
6. de Gruil F.R., and Rebel H. Early events in UV carcinogenesis-DNA damage, target cells and mutant p53 foci. Photochem. Photobiol. 84 (2008) 382-387
7. Germolec D.R., Yoshida T., Gaido K., Wilmer J.L., Simeonova P.P., Kayama F., Burleson F., Dong W., Lange R.W., and Luster M.I. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol. 141 (1996) 308-318
8. Harmand P.O., Duval R., Liagre B., Jayat-Vignoles C., Beneyout J.-L., Delage C., and Simon A. Ursolic acid induces apoptosis through caspase-3 activation and cell cycle arrest in HaCaT cells. Int. J. Oncol. 23 (2003) 105-112
9. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 (2005) 2899-2908
10. Hartwig A., Groblinghoff U.D., Beyersmann D., Natarajan A.T., Filon R., and Mullenders L.H.F. Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts. Carcinogenesis 18 (1997) 399-405
11. Hartwig A., Pelzer A., Asmuss M., and Burkle A. Very low concentrations of arsenite suppress poly(ADP-ribosyl)ation in mammalian cells. Int. J. Cancer 104 (2003) 1-6
12. Hofseth L.J., Hussain S.P., and Harris C.C. p53: 25 years after its discovery. Trends Pharmacol. Sci. 25 (2004) 177-181
13. Hu Y., Su L., and Snow E.T. Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat. Res. 408 (1998) 203-218
14. Huang Y., Zhang J., McHenry K.T., Kim M.M., Zeng W., Lopez-Pajares V., Dibble C.C., Mizgerd J.P., and Yuan Z.-M. Induction of cytoplasmic accumulation of p53: a mechanism for low levels of arsenic exposure to predispose cells for malignant transformation. Cancer Res. 68 (2008) 9131-9136
15. IARC (International Agency for Research on Cancer). Some drinking-water disinfectants and contaminants, including arsenic. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 84 (2004), IARC Press, Lyon 39-267
16. Kanai M., Hanashiro K., Kim S.-H., Hanai S., Boulares A.H., Miwa M., and Kukasawa K. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat. Cell Biol. 9 (2007) 1175-1183
17. Klein C.B., Leszczynska J., and Rossman T.G. Further evidence for a non-genotoxic MOA for arsenic-induced skin cancer. Toxicol. Appl. Pharmacol. 222 (2007) 289-297
18. Komissarova E.V., Saha S.K., and Rossman T.G. Dead or dying: the importance of time in cytotoxicity assays using arsenite as an example. Toxicol. Appl. Pharmacol. 202 (2005) 99-107
19. Kupper J.H., de Murcia G., and Burkle A. Inhibition of poly(ADP-ribosyl)ation by overexpressing the poly(ADP-ribose) polymerase DNA-binding domain in mammalian cells. J. Biol. Chem. 265 (1990) 18721-18724
20. Lehman T.A., Modali R., Boukamp P., Stanek J., Bennett W.P., Welsh J.A., Metcalf R.A., Stamfer M.R., Fusenig N., Rogan E.M., and Harris C.C. P53 mutations in human immortalized epithelial cell lines. Carcinogenesis 14 (1993) 833-839
21. Li J.-H., and Rossman T.G. Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis. Mol. Toxicol. 2 (1989) 1-9
22. Li Y., Jenkins C.W., Nichols M.A., and Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9 (1994) 2261-2268
23. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., and Jacks T. P53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9 (1995) 935-944
24. Malanga M., Pleschke J.M., Kleczkowska H.E., and Althaus F.R. Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions. J. Biol. Chem. 273 (1998) 11839-11843
25. Menard L., and Poirier G.G. Rapid assay of poly(ADP-ribose) glycohydrolase. Biochem. Cell Biol. 65 (1987) 668-673
26. Mendoza-Alvarez H., and Alvarez-Gonzalez R. Regulation of p53 sequence-specific DNA-binding by covalent poly(ADP-ribosyl)ation. J. Biol. Chem. 276 (2001) 36425-36430
27. Millau J.-F., Bastien N., and Drouin R. P53 transcriptional activities: a general overview and some thoughts. Mutat. Res. 681 (2009) 118-133
28. Millau J.-F., Bastien N., Bouchard E.F., and Drouin R. p53 pre- and post-binding event theories revisited: stresses reveal specific and dynamic p53-binding patterns on the p21 gene promoter. Cancer Res. 69 (2009) 8463-8471
29. Miwa M., and Masutani M. PolyADP-ribosylation and cancer. Cancer Sci. 98 (2007) 1528-1535
30. Mure K., Uddin A.N., Lopez L.K., Styblo M., and Rossman T.G. Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. Environ. Mol. Mutagen. 41 (2003) 322-331
31. NRC (National Research Council). Arsenic in Drinking Water (2000), National Academy Press, Washington DC, USA
32. Oei S.L., Keil C., and Ziegler M. Poly(ADP-ribosylation) and genomic stability. Biochem. Cell Biol. 83 (2005) 263-269
33. Okui T., and Fujiwara Y. Inhibition of human excision DNA repair by inorganic arsenic and the co-mutagenic effect in V79 Chinese hamster cells. Mutat. Res. 172 (1986) 69-76
34. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
35. Pfeifer G.P., and Besaratinia A. Mutational spectra of human cancer. Hum. Genet. 125 (2009) 493-506
36. Qin X.-J., Hudson L.G., Liu W., Timmins G.S., and Liu K.J. Low concentration of arsenite exacerbates UVR-induced DNA strand breaks by inhibiting PARP-1 activity. Toxicol. Appl. Pharmacol. 232 (2008) 41-50
37. Rossman T.G. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 533 (2003) 37-65
38. Rossman T.G. Arsenic. In: Rom W.N. (Ed). Environmental and Occupational Medicine, Fourth Edition (2007), Lippincott-Raven Publishers, Philadelphia 1006-1020
39. Rossman T.G., Uddin A., Burns F., and Bosland M. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol. Appl. Pharmacol. 176 (2001) 64-71
40. Satoh M.S., and Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 356 (1992) 356-358
41. Shaked H., Shiff I., Kott-Gutkowski M., Sigfried Z., Haupt Y., and Simon I. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines. Cancer Res. 68 (2008) 9671-9677
42. Smeenk L., van Heeringen S.J., Koeppel M., van Driel M.A., Bartels S.J.J., Akkers R.C., Denissov S., Stunnenberg H.G., and Lohrum M. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res. 36 (2008) 3639-3654
43. Soldatenkov V.A., Chasovskikh S., Potaman V.N., Trofimova I., Smulson M.E., and Dritschilo A. Transcriptional repression by binding of poly(ADP-ribose)polymerase to promoter sequences. J. Biol. Chem. 277 (2002) 665-670
44. Sun L., and Chen Z.J. The novel functions of ubiquitination in signaling. Curr. Opin. Cell Biol. 16 (2004) 119-126
45. Sun Y., Pi J., Wang X., Tokar E.J., Liu J., and Waalkes M.P. Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. Toxicology 262 (2009) 162-170
46. Tang F., Liu G., He Z., Ma W.-Y., Bode A.M., and Dong Z. Arsenite Inhibits p53 phosphorylation, DNA binding activity, and p53 target gene p21 expression in mouse epidermal JB6 Cells. Mol. Carcinog. 45 (2006) 861-870
47. Tinwell H., Stephens S.C., and Ashby J. Arsenite as the probable active species in the human carcinogenicity of arsenic: mouse micronucleus assay on Na and K arsenite, orpiment, and Fowler's solution. Environ. Health Perspect. 95 (1991) 205-210
48. Valenzuela M.T., Guerrero R., Nuňez M.I., de Almodovar J.M.R., Sarker M., de Murcia G., and Oliver F.J. PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 21 (2002) 1108-1116
49. Vaziri H., West M.D., Allsopp J.C., Davison T.S., Wu Y.u.-S., Arrowsmith C.H., Poirier G.G., and Benchimol S. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J. 16 (1997) 6018-6033
50. Vogt B.L., and Rossman T.G. Effects of arsenite on p53, p21, and cyclin D expression in normal human fibroblasts-a possible mechanism for arsenite's comutagenicity. Mutat. Res. 478 (2001) 159-168
51. Walter I., Schwerdtle T., Thuy C., Parsons J.L., Dianov G.L., and Hartwig A. Impact of arsenite and its methylated metabolites on PARP-1 activity, PARP-1 gene expression and poly(ADP-ribosyl)ation in cultured human cells. DNA Repair 6 (2007) 61-70
52. Wieler S., Garne J.-P.h., Vaziri H., Poirier G.G., and Benchimol S. Poly(ADP-ribose)polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J. Biol. Chem. 278 (2003) 18914-18921
53. Yager J.W., and Wiencke J.K. Inhibition of poly(ADP-ribose)polymerase by arsenite. Mutat. Res. 386 (1997) 345-351